Erin Bliven-Sizemore

Author

Centers for Disease Control and Prevention

Also Known As

E E Bliven-Sizemore, E. E. Bliven-Sizemore, Erin Bliven-Sizemore

Publications

1.5K

Citations

H-Index

Concepts

All Affiliations

Centers for Disease Control and Prevention The University of Texas Health Science Center at San Antonio Johns Hopkins University Johns Hopkins Medicine University of California, San Francisco

About

Erin Bliven-Sizemore is an author at Centers for Disease Control and Prevention specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	64
2	Natural Sciences	1	1	60
3	Biochemistry	1	1	24
4	Immunology	1	1	60
5	Medical Laboratory Science	1	1	24

Erin Bliven-Sizemore

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection Timothy R. Sterling, Margarita E. Villarino, Andrey Borisov, New England Journal of Medicine	2011	946
Effects of Tuberculosis, Race, and Human Gene <i>SLCO1B1</i> Polymorphisms on Rifampin Concentrations Marc Weiner, Charles A. Peloquin, William J. Burman, Antimicrobial Agents and Chemotherapy	2010	154
Safety and Pharmacokinetics of Escalating Daily Doses of the Antituberculosis Drug Rifapentine in Healthy Volunteers Kelly E. Dooley, Erin Bliven-Sizemore, Marc Weiner, Clinical Pharmacology & Therapeutics	2012	89
Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI Erin Bliven-Sizemore, Timothy R. Sterling, N. Shang, The International Journal of Tuberculosis and Lung Disease	2015	70
Aptamer-based proteomic signature of intensive phase treatment response in pulmonary tuberculosis Payam Nahid, Erin Bliven-Sizemore, Leah G. Jarlsberg, Tuberculosis Pulmonary TuberculosisNatural SciencesProteomicsImmunologyMolecular Biology	2014	60
Tuberculosis Biomarker and Surrogate Endpoint Research Roadmap Payam Nahid, Jussi Saukkonen, William R. Mac Kenzie, American Journal of Respiratory and Critical Care Medicine	2011	60
Population Pharmacokinetics of Rifapentine and Desacetyl Rifapentine in Healthy Volunteers: Nonlinearities in Clearance and Bioavailability Radojka M. Savić, Yanhui Lu, Erin Bliven-Sizemore, Antimicrobial Agents and Chemotherapy Quantitative PharmacologyPharmacotherapySystem PharmacologyPopulation PharmacokineticsPhysiologically-based Pharmacokinetic Modeling	2014	40
Optimising pyrazinamide for the treatment of tuberculosis Nan Zhang, Radojka M. Savić, Martin J. Boeree, European Respiratory Journal	2021	33
Quantification of Rifapentine, a Potent Antituberculosis Drug, from Dried Blood Spot Samples Using Liquid Chromatographic-Tandem Mass Spectrometric Analysis Teresa L. Parsons, Mark A. Marzinke, Thuy Hoang, Antimicrobial Agents and Chemotherapy Pharmaceutical ScienceWhole BloodPharmacotherapyPaired PlasmaDrug Resistance	2014	24
Decreased plasma rifapentine concentrations associated with <i>AADAC</i> single nucleotide polymorphism in adults with tuberculosis Marc Weiner, Jon Gelfond, Teresa L. Johnson‐Pais, Journal of Antimicrobial Chemotherapy	2020	18

Page 1